Short sale volume (not short interest) for $CNAT on 2018-08-24 is 48%. https://t.co/tbd1yH1hc6 $PFE 44% $VRTX 36% $ICPT 54% $IRWD 60%
RT @TomSilver39: GS sees Healthcare stocks which could outperform: $ABBV $PFE $MRK $CNC $WCG $MYL $ALXN $BMY $HOLX $ABC ...
GS sees Healthcare stocks which could outperform: $ABBV $PFE $MRK $CNC $WCG $MYL $ALXN $BMY $HOLX $ABC ...
$PFE $MRK $LLY $AGN:
Large-Cap Pharma Stocks Might Still Have Room to Rise Despite Recent Strength:
https://t.co/jwOvrGm0zk
2018-08-24 Short sale volume (not short interest) for $JNJ is 45%. https://t.co/Jzx0SHsUqa $SNY 66% $PFE 44% $LLY 64% $SYK 45%
RT @IBD_ECarson: Tesla Stock "Secured," But Sure To Be Active Monday; Futures https://t.co/jJ9d5jWzap $TSLA $PFE $ALNY $JNJ $BAYRY https://…
RT @IBD_ECarson: Tesla Stock "Secured," But Sure To Be Active Monday; Futures https://t.co/jJ9d5jWzap $TSLA $PFE $ALNY $JNJ $BAYRY https://…
RT @IBD_ECarson: Tesla Stock "Secured," But Sure To Be Active Monday; Futures https://t.co/jJ9d5jWzap $TSLA $PFE $ALNY $JNJ $BAYRY https://…
Tesla Stock "Secured," But Sure To Be Active Monday; Futures https://t.co/jJ9d5jWzap $TSLA $PFE $ALNY $JNJ $BAYRY https://t.co/rVNp12rHjo
Why we feel that $PTN Palatin Technology can soar to $5.00
Discussion includes $VRX $PFE $SNY $LLY
https://t.co/7DiZmTK7Jc
$PFE
9AM Analyst and Investor Call To Review Tafamidis Data Presentation at European Society of Cardiology Congres… https://t.co/OsLewMJCjC
RT @Benzinga: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results https://t.co/THdpBXfJR1 $PFE $AKCA $IONS $TTPH…
Tomorrow is my #birthday and I wouldn’t mind getting a present from $csco. Hoping the stock rallies, but no pressu… https://t.co/cTFyawrnpc
@JohnCendpts $PFE I assume? Still awaiting a catalyst for $SGMO
RT @adamfeuerstein: $PFE tafamidis data will be released tomorrow at 5 am EDT. $EIDX $ALNY
RT @AndyBiotech: #Biotech Busy final week of August
All eyes on $PFE Tafamidis data at #ESCcongress tomorrow --> $AKCA $IONS $ALNY $EIDX…
The Markets Are Undervaluing these stock's: Pfizer Inc. (PFE), The AES ... https://t.co/eSKbjXSDtJ $PFE #stocks #stockmarket
RT @adamfeuerstein: $PFE tafamidis data will be released tomorrow at 5 am EDT. $EIDX $ALNY
RT @permabear_uk: The core list
Tier 1: $INTC $BAC $MU $HD $PSX $GILD
Tier 2: $NVDA $JPM $AMD $TGT $APC $CELG
Tier 3: $MSFT $PYPL $AA…
RT @adamfeuerstein: I’ll be awake around 5:30 am tomorrow, so please have the $PFE tafamidis data analyzed and tweeted, the $ALNY $EIDX rea…
RT @adamfeuerstein: I’ll be awake around 5:30 am tomorrow, so please have the $PFE tafamidis data analyzed and tweeted, the $ALNY $EIDX rea…
RT @adamfeuerstein: $PFE tafamidis data will be released tomorrow at 5 am EDT. $EIDX $ALNY
RT @luan7038720: $PFE All time hight..#Breakout ⛳️⛳️⛳️ https://t.co/HyxfHDllcm
RT @OlympiaReport: Pfizer Inc. $PFE Expected to Post Quarterly Sales of $13.51 Billion https://t.co/mE6CZWWyba
RT @marcgarrigasait: Lista de directivos vendiendo mas del 10% de sus acciones en su empresa en agosto. Interesante RT @AndysCycles $MSFT $…
Leisure Capital Management Sells 10,321 Shares of Pfizer Inc. $PFE https://t.co/pcvSTL6lI2
Leisure Capital Management Sells 10,321 Shares of Pfizer Inc. $PFE https://t.co/KWpUMyMgiH
$ESPR $VKTX #LDL-L $NASH $PFE https://t.co/ysHybDRWd6
RT @permabear_uk: The core list
Tier 1: $INTC $BAC $MU $HD $PSX $GILD
Tier 2: $NVDA $JPM $AMD $TGT $APC $CELG
Tier 3: $MSFT $PYPL $AA…
@adamfeuerstein No wonder this weeks calls IV exploded with over 15 calls bought last week $PFE
Pfizer Inc. $PFE Expected to Post Quarterly Sales of $13.51 Billion https://t.co/mE6CZWWyba
Pfizer Inc. $PFE Expected to Post Quarterly Sales of $13.51 Billion https://t.co/BYlXGVRGoS
$PFE big 21k call volume options
$0.75 Earnings Per Share Expected for Pfizer Inc. $PFE This Quarter https://t.co/CzGa0hifE9
RT @adamfeuerstein: $PFE tafamidis data will be released tomorrow at 5 am EDT. $EIDX $ALNY
I’ll be awake around 5:30 am tomorrow, so please have the $PFE tafamidis data analyzed and tweeted, the $ALNY $EIDX… https://t.co/fuiamYBFNZ
RT @adamfeuerstein: $PFE tafamidis data will be released tomorrow at 5 am EDT. $EIDX $ALNY
RT @adamfeuerstein: $PFE tafamidis data will be released tomorrow at 5 am EDT. $EIDX $ALNY
RT @adamfeuerstein: $PFE tafamidis data will be released tomorrow at 5 am EDT. $EIDX $ALNY
$PFE tafamidis data will be released tomorrow at 5 am EDT. $EIDX $ALNY
The core list
Tier 1: $INTC $BAC $MU $HD $PSX $GILD
Tier 2: $NVDA $JPM $AMD $TGT $APC $CELG
Tier 3: $MSFT… https://t.co/6oRRf7FVLc
RT @AndyBiotech: #Biotech Busy final week of August
All eyes on $PFE Tafamidis data at #ESCcongress tomorrow --> $AKCA $IONS $ALNY $EIDX…
RT @AndyBiotech: #Biotech Busy final week of August
All eyes on $PFE Tafamidis data at #ESCcongress tomorrow --> $AKCA $IONS $ALNY $EIDX…
RT @AndyBiotech: #Biotech Busy final week of August
All eyes on $PFE Tafamidis data at #ESCcongress tomorrow --> $AKCA $IONS $ALNY $EIDX…
#estate asset watch - price volume leaders Friday - $BABA $NFLX $AMZN $AMD $AAPL $NVDA $FB $MSFT $SPK $ADSK $ANET… https://t.co/TApUavN5DB
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results
$ESPR $TGTX $AKCA $IONS $XENE $PFE… https://t.co/EKT5NagnMM
RT @ChinaBio: Week in Review: Three More China Biopharmas Planning Hong Kong IPOs $BNY $PFE $CBPO $BGNE $ZLAB https://t.co/i37gqUUNF7
RT @Benzinga: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results https://t.co/THdpBXfJR1 $PFE $AKCA $IONS $TTPH…
#estate asset watch - volume leaders Friday - $AMD $GERN $GGP $CRON $GE $BABA $BAC $CGC $DBX $MU $QD $CMCSA $GPS… https://t.co/MAmcgvxPAU
$PFE All time hight..#Breakout ⛳️⛳️⛳️ https://t.co/HyxfHDllcm
RT @AndyBiotech: #Biotech Busy final week of August
All eyes on $PFE Tafamidis data at #ESCcongress tomorrow --> $AKCA $IONS $ALNY $EIDX…
Large-Cap Pharma Stocks Might Still Have Room to Rise Despite Recent Strength $PFE https://t.co/Le0XQwUbdM https://t.co/kRNi8R4pkK
RT @bio_clouseau: WSJ editorial on how FDA made "right" call with $SRPT. A GT that produces the right "stuff" wouldn't be here right now if…
RT @Lin_ling_88: $ESPR $VKTX #LDL-L $NASH $PFE https://t.co/ysHybDRWd6
RT @arnabch01: @BPerrionni @semicvet50 @MontyNishimura @BrindusaB1 @RitaCobix @amparofashion @Papryka5 @PasqualeTotaro @dianadep1 @GaiaGaud…
RT @arnabch01: @BPerrionni @semicvet50 @MontyNishimura @BrindusaB1 @RitaCobix @amparofashion @Papryka5 @PasqualeTotaro @dianadep1 @GaiaGaud…
RT @arnabch01: @BPerrionni @semicvet50 @MontyNishimura @BrindusaB1 @RitaCobix @amparofashion @Papryka5 @PasqualeTotaro @dianadep1 @GaiaGaud…
RT @permabear_uk: The core list
Tier 1: $INTC $BAC $MU $HD $PSX $GILD
Tier 2: $NVDA $JPM $AMD $TGT $APC $CELG
Tier 3: $MSFT $PYPL $AA…
Doubled my account last week .. thanks to the option trades from https://t.co/K4Rhoz4a4X $CAT $MMM $INTC $INGR… https://t.co/Xj4mADbUkb
SunTrust Banks Raises Pfizer FY2022 Earnings Estimates to $3.76 EPS (Previously $3.74). https://t.co/2uKjODblZF $PFE #PFE
FY2022 EPS Estimates for Pfizer Inc. Lifted by SunTrust Banks $PFE https://t.co/ohvI22QAba
RT @permabear_uk: The core list
Tier 1: $INTC $BAC $MU $HD $PSX $GILD
Tier 2: $NVDA $JPM $AMD $TGT $APC $CELG
Tier 3: $MSFT $PYPL $AA…
$ROKU $SQ $VSTM $STAA $CTRL $TJX $FIVE $MPC $LLY $PFE $AMZN $ETSY $NBIX $KORS $AAPL $CBPX $ANET $GRUB $DLTH $QQQ $TQQQ $SPY
Pfizer $PFE Given Buy Rating at JPMorgan Chase & Co. https://t.co/RVn64YvcZw
Short sale volume (not short interest) for $PFE at 2018-08-24 is 44%. https://t.co/YezYNYnVQm $LLY 64% $MRK 47% $BMY 19% $JNJ 45%
Top 5 LT momentum stocks of the Dow 30: $MRK $PFE $AAPL $V $NKE
Bottom 5: $IBM $MMM $XOM $INTC $CVX… https://t.co/p5ErdiRhqb
Top 5 ST momentum stocks of the Dow 30: $MRK $CSCO $JNJ $AAPL $PFE
Bottom 5: $XOM $INTC $KO $DIS $CVX… https://t.co/z91JIJEKcX
Top 5 LT momentum stocks of the S&P 100: $LLY $QCOM $AMZN $MRK $PFE
Bottom 5: $FB $GM $HAL $GE $F… https://t.co/nR9RZYoY6L
$opgn $mrk $rhhby $pfe
OpGen has a prominent role to address the rising antibiotic resistance crisis.
RT @AndersenBands: Top 5 LT momentum stocks of the Dow 30: $MRK $PFE $AAPL $V $NKE
Bottom 5: $IBM $MMM $XOM $INTC $CVX https://t.co/1gV…
80mg might be construed as showing slight improvement over 20mg when looking on an absolute basis. $PFE $EIDX $ALNY… https://t.co/Fv3npOHdFy
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
@RNAiAnalyst Given the somewhat "complementary" MOAs, I suppose a tafamidis + patisiran or
ALN-TTRsc02 combination… https://t.co/7Ly9bMNeN7
RT @theflynews: $ALNY $PFE $EIDX https://t.co/XyhPJj0Lla
$ALNY $PFE $EIDX https://t.co/XyhPJj0Lla
RT @RNAiAnalyst: Congrats to $PFE for sticking with Tafamidis despite early lackluster commercial results; but RNAi still looks far superio…
This week’s trading ideas are up at https://t.co/Ki2ykqWZEc. $BBY $TIF $HRB $CRM $PVH $DKS $DLTR $LULU $ULTA $SPY… https://t.co/SrDXNIEeAz
RT @adamfeuerstein: $PFE tafamidis data will be released tomorrow at 5 am EDT. $EIDX $ALNY
Congrats to $PFE for sticking with Tafamidis despite early lackluster commercial results; but RNAi still looks far superior... $ALNY
$PFE $Eidx Plenty of upside for competition. would have liked larger dose response. huge error bars on both 80 and… https://t.co/SGnftVyJEY
RT @odibro: $PFE Tafamidis Phase 3 ATTR-ACT Significantly Reduced the Combination of All-cause Mortality and Cardiovascular-related Hospita…
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
RT @odibro: $PFE Tafamidis Phase 3 ATTR-ACT Significantly Reduced the Combination of All-cause Mortality and Cardiovascular-related Hospita…
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
RT @RNAiAnalyst: Jackpot $ALNY! $PFE $AKCA $IONS https://t.co/9RrXpAHZrh
RT @lukebiotech: Tafamidis shows benefit while leaving plenty of room for improvement
$EIDX $PFE $ALNY #IONS #ATTR #ESCCongress https://t.c…
Tafamidis shows benefit while leaving plenty of room for improvement
$EIDX $PFE $ALNY #IONS #ATTR #ESCCongress https://t.co/50Uw8dYhrG
Good $PFE data but basically in line with expectations, so $ALNY should still be higher today. Tafamidis leaves roo… https://t.co/nskKoHWRyD
IF I must be very picky, and find a fly in the ointment from this $PFE Tafamidis data implication - is it too robus… https://t.co/zEDH60mU99
Jackpot $ALNY! $PFE $AKCA $IONS https://t.co/9RrXpAHZrh
RT @ByMadeleineA: $PFE’s tafamidis reduces risk of mortality by 30% and CV-related hospitalisations by 32% in amyloidosis. Looks good on th…
RT @ByMadeleineA: Most docs in the #ESCCongress audience would consider tafamidis in all patients with amyloid cardiomyopathy $PFE https://…
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
$PFE Tafamidis Phase 3 ATTR-ACT Significantly Reduced the Combination of All-cause Mortality and Cardiovascular-rel… https://t.co/jNtiEZ4wEc
RT @ByMadeleineA: Most docs in the #ESCCongress audience would consider tafamidis in all patients with amyloid cardiomyopathy $PFE https://…
#Tafamidis Phase 3 #Transthyretin Amyloid #Cardiomyopathy (#ATTR-ACT) Study Results Presented as Late-Breaking Data… https://t.co/y74rwypwkH
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
Most docs in the #ESCCongress audience would consider tafamidis in all patients with amyloid cardiomyopathy $PFE https://t.co/1zbQGm7fiz
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
RT @ByMadeleineA: $PFE’s tafamidis reduces risk of mortality by 30% and CV-related hospitalisations by 32% in amyloidosis. Looks good on th…
Pfizer $PFE Given a $45.00 Price Target by Morgan Stanley Analysts https://t.co/DjatxvsjNb
RT @JohnCendpts: BREAKING: Pfizer wows cardio crowd with game-changing mortality and hospitalization rates for tafamidis in ATTR-CM
$PFE
ht…
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
Pfizer $PFE Stock Rating Reaffirmed by JPMorgan Chase & Co. https://t.co/5Mvz2kK5yK
Pfizer $PFE Stock Rating Reaffirmed by JPMorgan Chase & Co. https://t.co/ESFiVrY8zV
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
RT @portefeuillefun: #Tafamidis Treatment for Patients with #Transthyretin Amyloid Cardiomyopathy https://t.co/EvD4tMgvpJ. $PFE $ALNY $IONS…
more #tafamidis data. $PFE $ALNY $IONS #ATTR #ESCCongress #ESC2018 https://t.co/Ci3dfUmcQ4
$PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win… https://t.co/Jbf43mG8K4
Mortality analysis from that publication. $PFE $ALNY $IONS #tafamidis #ATTR #ESCCongress #ESC2018 https://t.co/JCCTsEUlxz
Stabilizing #Transthyretin to Treat #ATTR #Cardiomyopathy https://t.co/TgKWC3PUpB. $PFE $ALNY $IONS #tafamidis #ATTR #ESCCongress #ESC2018
RT @portefeuillefun: #Tafamidis Treatment for Patients with #Transthyretin Amyloid Cardiomyopathy https://t.co/EvD4tMgvpJ. $PFE $ALNY $IONS…
#Tafamidis Treatment for Patients with #Transthyretin Amyloid Cardiomyopathy https://t.co/EvD4tMgvpJ. $PFE $ALNY… https://t.co/1lyb90VIzn
RT @ByMadeleineA: And secondary endpoint data with tafamidis $PFE #ESCCongress https://t.co/YkYagwL83S
Pfizer rare heart disease drug reduces risk of death by 30 percent in study https://t.co/nYV9Ffl7C9. $PFE $ALNY… https://t.co/4c29A2EzDB
RT @ByMadeleineA: Here’s the primary endpoint curve for tafamidis in Attra-act trial in amyloidosis $PFE #ESCcongress https://t.co/m5shnqW3…
RT @ByMadeleineA: $PFE’s tafamidis reduces risk of mortality by 30% and CV-related hospitalisations by 32% in amyloidosis. Looks good on th…
RT @ByMadeleineA: At press conference this morning, Dr Claudio Rapezzi wouldn’t break down performance of 20mg vs 80mg dose of tafamidis, o…
RT @ByMadeleineA: $PFE’s tafamidis reduces risk of mortality by 30% and CV-related hospitalisations by 32% in amyloidosis. Looks good on th…
At press conference this morning, Dr Claudio Rapezzi wouldn’t break down performance of 20mg vs 80mg dose of tafami… https://t.co/R6QbyvjM44
@ByMadeleineA Looks pretty as well :) #tafamidis $PFE
RT @ByMadeleineA: Here’s the primary endpoint curve for tafamidis in Attra-act trial in amyloidosis $PFE #ESCcongress https://t.co/m5shnqW3…
@ByMadeleineA Looks pretty! #tafamidis $PFE
RT @ByMadeleineA: $PFE’s tafamidis reduces risk of mortality by 30% and CV-related hospitalisations by 32% in amyloidosis. Looks good on th…
RT @ByMadeleineA: And secondary endpoint data with tafamidis $PFE #ESCCongress https://t.co/YkYagwL83S
And secondary endpoint data with tafamidis $PFE #ESCCongress https://t.co/YkYagwL83S
RT @JohnCendpts: BREAKING: Pfizer wows cardio crowd with game-changing mortality and hospitalization rates for tafamidis in ATTR-CM
$PFE
ht…
Here’s the primary endpoint curve for tafamidis in Attra-act trial in amyloidosis $PFE #ESCcongress https://t.co/m5shnqW34D
RT @ByMadeleineA: $PFE’s tafamidis reduces risk of mortality by 30% and CV-related hospitalisations by 32% in amyloidosis. Looks good on th…
Biotwitter appears to see #patisiran & #ALNTTRsc02 as the most likely winner of the #ATTR drug race… https://t.co/8CxSCw7QjV
$PFE’s tafamidis reduces risk of mortality by 30% and CV-related hospitalisations by 32% in amyloidosis. Looks good… https://t.co/eAuX8S63i3
BREAKING: Pfizer wows cardio crowd with game-changing mortality and hospitalization rates for tafamidis in ATTR-CM… https://t.co/hj0kvPjzyw
The #tafamidis presentation starts in a few minutes -> #ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transt… https://t.co/HYvGJYkDWD
RT @ByMadeleineA: ESC 2018 – Xarelto again fails to Command an advantage $JNJ $BMY $PFE #ESCCongress via @Vantageanalysis https://t.co/tPXb…
@AndyBiotech Congrats to $pfe on amazing results. Expect this to be a huge blockbuster and get 80% of a very large… https://t.co/5UxgxKZ9Wd
@JohnCendpts Funny in the 10 min I’ve had tape on I’ve only seen $pfe once, teeny bit higher, and $alny not at all. Does that surprise you?
ESC 2018 – Xarelto again fails to Command an advantage $JNJ $BMY $PFE #ESCCongress via @Vantageanalysis https://t.co/tPXbtIeOH4
@adamfeuerstein Seriously? $pfe data is a homerun. $alny will be stuck fighting WITH $akca inotersen over 6000… https://t.co/aCmxWcJtPC
Seriously? $pfe data is a homerun. $alny will be stuck fighting WITH $akca inotersen over 6000 #Amyloidosis neuropathy pts in US AND EU
@JohnCendpts The $pfe data is a homerun. $alny smoking crack if they think otherwise
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
RT @JohnCendpts: Whoa! $ALNY strikes back in record time, highlights weaknesses in $PFE's tafamidis case.
https://t.co/iBsWrp3JvC
@abouezzeddine @MayoClinicCV @MarthaGrogan1 @matthewmaurer @escardio $pfe Tafamidis is a homerun in cardiac… https://t.co/Zf99ungOWd
The tafamidis paper only presented pooled analysis of two doses (20 and 80mg). Guess no clear dose response. In a… https://t.co/p1UojCo1VW
$PFE Reveals Tafamidis Late-Stage Transthyretin Cardiomyopathy Study Findings https://t.co/QBeCL1Gj33
Whoa! $ALNY strikes back in record time, highlights weaknesses in $PFE's tafamidis case.
https://t.co/iBsWrp3JvC
RT @adamfeuerstein: Good $PFE data but basically in line with expectations, so $ALNY should still be higher today. Tafamidis leaves room fo…
RT @adamfeuerstein: Good $PFE data but basically in line with expectations, so $ALNY should still be higher today. Tafamidis leaves room fo…
Btw, Estimated #Earnings Per Share for $PFE is $0.56 it's 1.32% of the current price https://t.co/pOf6lum9ag
$PFE Announces primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study. The study… https://t.co/x2Fs22tXVe
RT @AndyBiotech: #Biotech Busy final week of August
All eyes on $PFE Tafamidis data at #ESCcongress tomorrow --> $AKCA $IONS $ALNY $EIDX…
@RNAiAnalyst Ok, and let's add a few #inotersen injections on top :) $PFE $ALNY $IONS $AKCA
RT @adamfeuerstein: Good $PFE data but basically in line with expectations, so $ALNY should still be higher today. Tafamidis leaves room fo…
RT @ByMadeleineA: ESC 2018 – Xarelto again fails to Command an advantage $JNJ $BMY $PFE #ESCCongress via @Vantageanalysis https://t.co/tPXb…
Some of todays top open interest changes 8.27.18 $GGP $LB $F $PFE $VALE $AMD $FB $MU $ABX $ROST https://t.co/zkZAGZIr0D
RT @matthewherper: Pfizer Drug Reduces Death Rate In Patients With Hearts Damaged By Protein Clumps $PFE RALNY $EIDX https://t.co/mXm4g8fwTg
Pfizer Drug Reduces Death Rate In Patients With Hearts Damaged By Protein Clumps $PFE RALNY $EIDX https://t.co/mXm4g8fwTg
RT @AppleHelix: Biotech PSA #[don't remember]. Give credit to $PFE for allowing the entire 281-pg tafamidis Ph 3 protocol to be published w…
RT @JohnCendpts: Whoa! $ALNY strikes back in record time, highlights weaknesses in $PFE's tafamidis case.
https://t.co/iBsWrp3JvC
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
$PFE Pfizer's tafamidis shows positive effect in late-stage ATTR-CM study; shares up 1% premarket https://t.co/Dz91FmmhX6
$ALNY should drop today off this $PFE Data.
$PFE flat
$ALNY +1%
$AMRN flat
Last. Week. In. August.
Big Call Activity https://t.co/XVFfGAORkO … $M $MA $MCD $MDT $MIC $MKSI $MLM $MO $MOS $MPC $MRO $MSFT $MTZ $MU $MYL… https://t.co/Dmt3GJKhWI
Pfizer's tafamidis shows positive effect in late-stage ATTR-CM study; shares up 1% premarket https://t.co/3KOzJRIJFl #premarket $PFE
@recervan I also have $ABBV , $PFE
Up early for the $PFE #amyloidosis data. Great response by $ALNY given that patisiran and tafamidis will be somewha… https://t.co/w5hXrbPxwj
Ep. 9 "Can #keto kill you" of our @ArmchairHealth podcast is up! Here's a guide:
00:47 - The study which said low… https://t.co/WOahinGHW2
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
$PFE study shows results are positive from tafamidis study
Biotech PSA #[don't remember]. Give credit to $PFE for allowing the entire 281-pg tafamidis Ph 3 protocol to be pub… https://t.co/h6ANgE2SZa
$pfe 52 week high pre mkt releases phase 3 results - still away from record high in late 90s early 2000s
RT @UPBOptionMil: Some of todays top open interest changes 8.27.18 $GGP $LB $F $PFE $VALE $AMD $FB $MU $ABX $ROST https://t.co/zkZAGZIr0D
RT @fklivestolearn: PRE Market Movers: $TSLA, $UAL, $TWTR, $NFLX, $DVMT, $CWK, $CA, $PFE, $JNJ, $CMG, $BABA, $IQ, $BIDU, $JD, $CRON, $TLRY,…
RT @fklivestolearn: PRE Market Movers: $TSLA, $UAL, $TWTR, $NFLX, $DVMT, $CWK, $CA, $PFE, $JNJ, $CMG, $BABA, $IQ, $BIDU, $JD, $CRON, $TLRY,…
PRE Market Movers: $TSLA, $UAL, $TWTR, $NFLX, $DVMT, $CWK, $CA, $PFE, $JNJ, $CMG, $BABA, $IQ, $BIDU, $JD, $CRON,… https://t.co/y3bq2zTtiE
Stocks Making The Biggest Moves PM: $TSLA $UAL $TWTR $NFLX $DVMT $PFE $JNJ $JD $BIDU $IQ $BABA $CMG & More https://t.co/Fec2MQPGaZ
RT @fklivestolearn: PRE Market Movers: $TSLA, $UAL, $TWTR, $NFLX, $DVMT, $CWK, $CA, $PFE, $JNJ, $CMG, $BABA, $IQ, $BIDU, $JD, $CRON, $TLRY,…
RT @drastichs: #stocks #ETF & #funds to #review #alphabetically
$PCG $PCTY $PDCO $PDEX $PDFS $PEGI $PFE $PG $PGNX $PHI $PHIIK $PM $PNM $PN…
#stocks #ETF & #funds to #review #alphabetically
$PCG $PCTY $PDCO $PDEX $PDFS $PEGI $PFE $PG $PGNX $PHI $PHIIK $PM… https://t.co/pZZp5Q1QN6
RT @EmergingGrowth1: $PTN Why we think Palatin Technologies, Inc. (NYSE: PTN) can soar to $5.00 per share
https://t.co/7DiZmTK7Jc
$VRX $PFE…
RT @EmergingGrowth1: $PTN Why we think Palatin Technologies, Inc. (NYSE: PTN) can soar to $5.00 per share
https://t.co/7DiZmTK7Jc
$VRX $PFE…
RT @marcgarrigasait: Lista de directivos vendiendo mas del 10% de sus acciones en su empresa en agosto. Interesante RT @AndysCycles $MSFT $…
RT @odibro: $PFE Tafamidis Phase 3 ATTR-ACT Significantly Reduced the Combination of All-cause Mortality and Cardiovascular-related Hospita…
Pre-opening comments on $TSLA $EWW $PFE. See:
https://t.co/pUCdCQgTvp
#HODL #cryptocurrency #stockstowatch #Commodities #indices $QTUM $ADA $ZIL $wan $Srpt $XRP $ETH $DAPS $CYFM $rsls… https://t.co/4m14im9Vqz
$QCOM $GGP $PFE $AMD $FB $ABX $AVEO $ROST $VALE $PFE $SYMC $NXPI $TRXC $BABA $ABAX $F $CSCO $PRB $GE $HTZ $F Larges… https://t.co/l8fWwc71AY
@buysidebio Well $EIDX is the one who set the expectation, not $PFE :)
RT @ByMadeleineA: ESC 2018 – Xarelto again fails to Command an advantage $JNJ $BMY $PFE #ESCCongress via @Vantageanalysis https://t.co/tPXb…
RT @JohnCendpts: Whoa! $ALNY strikes back in record time, highlights weaknesses in $PFE's tafamidis case.
https://t.co/iBsWrp3JvC
PM MOVERS
$NFLX $BABA $UAL $TWTR $JNJ $BIDU $IQ $PFE $CRON $TSLA $CWK $TLRY $DVMT $JD $BILI $CMG $PTLA $CA
RT @OpenOutcrier: $PFE (+0.9% pre) Pfizer's rare heart disease drug reduces risk of death by 30% in study
https://t.co/8gCVQwig4S
$PFE (+0.9% pre) Pfizer's rare heart disease drug reduces risk of death by 30% in study
https://t.co/8gCVQwig4S
$alny bouncing on $pfe data release
NEJM editorial take on tafamidis data. $PFE $ALNY $AKCA https://t.co/7JaNY043cb
$PFE + PR
@avidresearch so give up comparing altogether? on the polyneuropathy side of the $PFE trial, $ALNY seems also to be… https://t.co/mLxFJcg5QG
@avidresearch @RNAiAnalyst $alny label only allows to market in neuropathy because the cardiac data was weak.The nt… https://t.co/CokMiozhKe
@RNAiAnalyst Nope, the $ALNY home-run scenario is for $PFE to instruct all its reps to do an awful job on detailing… https://t.co/SIpH2YSGWE
@RNAiAnalyst $ALNY $PFE subjects in studies are at very different risk levels. $PFE trial subjects appear to be mor… https://t.co/VDiGGwxsb6
Beijing this month said it was in negotiations with foreign companies over the price of 18 cancer drugs, including… https://t.co/3HrRgsbVsS
$ALNY home-run scenario: $PFE tafamidis data shows large market there for RNAi, but tafamidis unsuccessful where… https://t.co/i8E0V3scjC
$PTN Why we think Palatin Technologies, Inc. (NYSE: PTN) can soar to $5.00 per share
https://t.co/7DiZmTK7Jc
$VRX… https://t.co/WedULFKHYa
$ALNY relief rally -- +5%
$PFE up a tad bit.
https://t.co/iBsWrp3JvC
$PFE
Pfizer rare heart disease drug reduces risk of death by 30 pct in study https://t.co/A7dft965AH via @YahooFinance
overall, $ALNY seems to win on biomarker data, just needs to run a longer trial to prove mortality benefit. $PFE
RT @RNAiAnalyst: $ALNY left ventrical wall thickness at 18 months -1.0 vs -0.11 for Tafamidis at 30. Take that, $PFE: https://t.co/GfYK2MfN…
$ALNY left ventrical wall thickness at 18 months -1.0 vs -0.11 for Tafamidis at 30. Take that, $PFE: https://t.co/GfYK2MfN4N
Pfizer's tafamidis shows positive effect in late-stage ATTR-CM study; shares up 1% premarket https://t.co/VjHqSagE0h $PFE
$PFE: Pfizer announces primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study https://t.co/bqiMTNCWHi
RT @gcbioinv: My take on $PFE tafamidis
-SS mortality ~30% and CV hosp ~32% in WT pts, trend in TTRm
-Weak dose response
+ve for $ALNY du…
RT @AndyBiotech: $PFE Tafamidis Ph3 ATTR-ACT data out in NEJM
https://t.co/ygEk6fIuHM
https://t.co/nQnSuVtUUK
- Primary endpt win ratio =…
My take on $PFE tafamidis
-SS mortality ~30% and CV hosp ~32% in WT pts, trend in TTRm
-Weak dose response
+ve fo… https://t.co/PG0Y8UxcF9
$PFE tafamidis data pretty solid, hard to make compelling case that there is much real readthru to $ALNY $IONS - pu… https://t.co/2qn6cslCGU
The liquidity in $PFE $ALNY $IONS $EIDX pre-market is breathtaking
Pre-market movers https://t.co/DJIQBqgzDB $JD $BABA $IQ $CMG $BIDU $JNJ $PFE $AVGO $NFLX $CWK $UAL $TSLA $TWTR $DVMT